Nevro Corp (NYSE:NVRO), a medical device company specializing in spinal cord stimulation (SCS) technology for chronic pain treatment, has recently undergone significant changes in its market ...

August 20, 2024 — 01:04 pm EDT Written by Zacks Equity Research for Zacks -> Nevro Corp. NVRO is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) edge.

Nevro Corp.'s shares hit fresh lows after revenue guidance reset, reflecting stagnant growth and substantial losses. Learn more about NVRO stock here.

Nevro Corp (NVRO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on December 1. Analyst William Plovanic from Canaccord Genuity remains neutral on the ...

Based on Nevro Corp’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $104.16 million and a GAAP net loss of $19.58 million. In comparison ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Nevro Corp. (NVRO) on Tuesday reported a loss of $53.1 million in its fourth quarter. On a per-share basis, the Redwood City, California ...

Nevro Corp. (NVRO) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Angie McCabe - Vice President, Investor Relations & Corporate Communications Kevin Thornal - CEO and ...

Nevro Corp. NVRO is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) edge. The optimism led by a solid first-quarter 2024 performance and continued ...

The U.S. commercial launch of Nevro's proprietary 10 kHz High Frequency SCS Therapy for PDN, post its FDA approval in late July 2021, raises optimism in the stock.